Burnside J, Costello J M, Angelastro N J, Blankenship J
Department of Cardiology, Geisinger Medical Center, Danville, Pennsylvania 17822.
Clin Cardiol. 1994 Jun;17(6):345-7. doi: 10.1002/clc.4960170614.
Thrombolytic therapy for myocardial infarction may contribute to bleeding complications when central venous or arterial access is required, but peripheral venous access is usually uncomplicated. We report a patient in whom tissue plasminogen activator and subsequent intravenous heparin exacerbated bleeding from a disrupted intravenous access site, leading to acute compartment syndrome requiring surgical decompression. This case emphasizes the risks associated with iatrogenic trauma during thrombolytic therapy.
心肌梗死的溶栓治疗在需要中心静脉或动脉通路时可能会导致出血并发症，但外周静脉通路通常不会出现并发症。我们报告了一例患者，组织型纤溶酶原激活剂及随后的静脉注射肝素加剧了静脉穿刺部位破裂导致的出血，进而引发急性骨筋膜室综合征，需要手术减压。该病例强调了溶栓治疗期间医源性创伤相关的风险。
